Pages

▼
Showing posts with label Buy-and-Bill. Show all posts
Showing posts with label Buy-and-Bill. Show all posts
Tuesday, July 14, 2026

Medicare Embraces Site-Neutral Payments. Why Haven't Employers?

›
By Bryce Platt, PharmD Provider-administered drugs are one of the fastest-growing and least-managed cost drivers for commercial plan spons...
Tuesday, February 24, 2026

Drug Channels News Roundup, February 2026: Mark Cuban on FTC-ESI, What Patients Really Want, QALYs vs. MFN, 340B’s Site of Care Shift, and New Faces at DCI

›
By Adam J. Fein, Ph.D. Despite the recent storm, winter—or at least February—is almost over. Before we thaw out, here’s a brisk tour of the ...
Thursday, December 11, 2025

The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers’ Vertical Integration with Physician Practices (rerun)

›
This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Outlook 2026 . Click here...
Tuesday, October 21, 2025

The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers’ Vertical Integration with Physician Practices

›
Vertical integration continues to reshape U.S. healthcare, as detailed in DCI’s new 2025-26 Economic Report on Pharmaceutical Wholesalers an...
Tuesday, October 14, 2025

NOW AVAILABLE: The 2025–26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

›
I am pleased to announce Drug Channels Institute’s new 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors ...
Wednesday, September 17, 2025

Preorder Now: DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

›
On October 14, 2025, Drug Channels Institute will release our 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distri...
Tuesday, August 19, 2025

Drug Channels News Roundup, August 2025: White Bagging Battles, Private Label Price Hypocrisy, 340B Patient Problems, and UnitedHealth Group’s Woes

›
Our news-laden summer is ending. Time to pack away your bathing suit, send the kids back to school, and cherish these curated curiosities th...
Tuesday, August 05, 2025

Markup Madness 2025: Hospitals, Insurers, and the Broken Buy-and-Bill Market for Biosimilars

›
After multiple years of mandated disclosure of negotiated hospital-insurer rates, those of us who follow the buy-and-bill channel might have...
Wednesday, May 21, 2025

How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs

›
The Inflation Reduction Act (IRA) is triggering increases in Medicare beneficiaries’ spending on their Part B drugs. Though CMS touts that ...
Thursday, April 03, 2025

Vertical Integration Redux: How Pharmaceutical Wholesalers Are Transforming the Buy-and-Bill Market (rerun)

›
This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: PBM Industry Update: Trends, Challenges, and ...
Tuesday, February 04, 2025

Vertical Integration Redux: How Pharmaceutical Wholesalers Are Transforming the Buy-and-Bill Market (Video)

›
ICYMI, the largest three pharmaceutical wholesalers—Cardinal Health, Cencora, and McKesson—are using vertical integration to build significa...
Thursday, December 12, 2024

White Bagging Update 2024: Providers’ Pushback Preserves Buy-and-Bill (rerun)

›
This week, I’m rerunning some popular posts while I prepare for tomorrow’s Drug Channels Outlook 2025 live video webinar. During the webin...
Monday, November 04, 2024

Transparency Shocker: Biosimilars Are Getting Cheaper—But Hospitals and Insurers Can Make Them Expensive

›
Here on Drug Channels , we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacy market, adoption...
Tuesday, October 29, 2024

Drug Channels News Roundup, October 2024: Humira Price War Update, PA vs. Providers, IRA vs. Physicians, My AI Podcast, New DCI Jobs, and Dr. G on Copayments

›
Eeek! It's time for Drug Channels’ Halloween roundup of terrifying tales to share with your ghoulish fiends. This month’s tricks and tr...
Thursday, October 03, 2024

Another IRA Surprise: Part B Coinsurance Inflation Adjustments Are Increasing Patient Costs (rerun)

›
This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholes...
Tuesday, September 24, 2024

Drug Channels News Roundup, September 2024: Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

›
Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these acorns that we’ve squirrelled away for you: Johnson & Joh...
Tuesday, September 17, 2024

Available for Preorder: The 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

›
On October 8, 2024, Drug Channels Institute will release our  2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributo...
Wednesday, September 11, 2024

White Bagging Update 2024: Providers’ Pushback Preserves Buy-and-Bill

›
Time for DCI’s annual update on the channels for provider-administered drugs. Below, I review the latest data on 2024 trends and compare the...
Tuesday, May 14, 2024

Another IRA Surprise: Part B Coinsurance Inflation Adjustments Are Increasing Patient Costs

›
Contrary to what you may have heard, the Inflation Reduction Act’s (IRA) inflation rebates for Medicare Part B drugs do not always save mone...
Thursday, December 14, 2023

The Battle for Oncology Margin: How Private Equity Enables Vertical Integration by Pharmaceutical Wholesalers (rerun)

›
This week, I’m rerunning some popular posts while I prepare for tomorrow’s Drug Channels Outlook 2024 live video webinar. Click here to see...